In vitro activity of tigecycline and comparators (2014–2016) among key WHO ‘priority pathogens’ and longitudinal assessment (2004–2016) of antimicrobial resistance: a report from the T.E.S.T. study

International Journal of Antimicrobial Agents

Volumn 52, Issue 4, 2018, Pages 474-484

  Seifert, Harald ^a   Blondeau, Joseph ^b   Dowzicky, Michael J ^c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b SASKATOON HEALTH REGION   (Canada)

^c PFIZER INC   (United States)

Author keywords

Antimicrobial resistance; Global; Priority pathogens; Surveillance; Tigecycline; World Health Organization

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CLARITHROMYCIN; CLINDAMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MINOCYCLINE; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE;

ACINETOBACTER BAUMANNII; AFRICA; ANTIBIOTIC RESISTANCE; ARTICLE; ASIA; ENTEROBACTERIACEAE; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MIC90; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORTH AMERICA; PRIORITY JOURNAL; SERRATIA MARCESCENS; SOUTH AMERICA; DRUG EFFECT; ENTEROBACTER; EPIDEMIOLOGICAL MONITORING; EUROPE; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; GROWTH, DEVELOPMENT AND AGING; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE;

ACINETOBACTER BAUMANNII; AFRICA; ANTI-BACTERIAL AGENTS; ASIA; CARBAPENEMS; CEFTRIAXONE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTER; ENTEROCOCCUS FAECIUM; EPIDEMIOLOGICAL MONITORING; ESCHERICHIA COLI; EUROPE; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; KLEBSIELLA PNEUMONIAE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; NORTH AMERICA; SERRATIA MARCESCENS; SOUTH AMERICA; TIGECYCLINE;

EID: 85051718459     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2018.07.003     Document Type: Article

References (36)

1. World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. 2017, WHO, Geneva, Switzerland http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf [accessed 24 July 2017].
2. van Duin, D, Doi, Y, The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence 8 (2017), 460–469.
3. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2015. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). 2017, ECDC, Stockholm, Sweden https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/antimicrobial-resistance-europe-2015.pdf [accessed 24 July 2017].
4. Sader, HS, Castanheira, M, Farrell, DJ, Flamm, RK, Mendes, RE, Jones, RN, Tigecycline antimicrobial activity tested against clinical bacteria from Latin American medical centres: results from SENTRY antimicrobial surveillance program (2011–2014). Int J Antimicrob Agents 48 (2016), 144–150.
5. Sader, HS, Farrell, DJ, Flamm, RK, Jones, RN, Variation in potency and spectrum of tigecycline activity against bacterial strains from U.S. medical centers since its approval for clinical use (2006 to 2012). Antimicrob Agents Chemother 58 (2014), 2274–2280.
6. Mendes, RE, Mendoza, M, Banga Singh, KK, Castanheira, M, Bell, JM, Turnidge, JD, et al. Regional resistance surveillance program results for 12 Asia-Pacific nations (2011). Antimicrob Agents Chemother 57 (2013), 5721–5726.
7. Hoban, DJ, Reinert, RR, Bouchillon, SK, Dowzicky, MJ, Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004–2013. Ann Clin Microbiol Antimicrob, 14, 2015, 27.
8. Rodloff, AC, Dowzicky, MJ, Antimicrobial susceptibility among European Gram-negative and Gram-positive isolates collected as part of the Tigecycline Evaluation and Surveillance Trial (2004–2014). Chemotherapy 62 (2017), 1–11.
9. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. Tenth edition, 2015, CLSI, Wayne, PA Document M07-A10.
10. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 2017, CLSI, Wayne, PA Document M100S, 27th ed.
11. US Food and Drug Administration (FDA). Tigecycline FDA prescribing information. 2016 Revised December 2016 https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205645lbl.pdf [accessed 16 October 2017].
12. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 7.1, 2017. 2017, EUCAST http://www.eucast.org [accessed 20 July 2018].
13. Karaiskos, I, Giamarellou, H, Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother 15 (2014), 1351–1370.
14. Paul, M, Carmeli, Y, Durante-Mangoni, E, Mouton, JW, Tacconelli, E, Theuretzbacher, U, et al. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother 69 (2014), 2305–2309.
15. Gales, AC, Jones, RN, Sader, HS, Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY antimicrobial surveillance program (2006–09). J Antimicrob Chemother 66 (2011), 2070–2074.
16. Giske, CG, Contemporary resistance trends and mechanisms for the old antibiotics colistin, temocillin, fosfomycin, mecillinam and nitrofurantoin. Clin Microbiol Infect 21 (2015), 899–905.
17. Falagas, ME, Kasiakou, SK, Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 40 (2005), 1333–1341.
18. Nowak, J, Zander, E, Stefanik, D, Higgins, PG, Roca, I, Vila, J, et al. High incidence of pandrug-resistant Acinetobacter baumannii isolates collected from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial. J Antimicrob Chemother 72 (2017), 3277–3282.
19. KPC into bacterial species beyond Klebsiella pneumoniae and in vitro susceptibility to ceftazidime–avibactam and aztreonam–avibactam. Antimicrob Agents Chemother 60 (2016), 4490–4500.
20. Mezzatesta, ML, Gona, F, Caio, C, Petrolito, V, Sciortino, D, Sciacca, A, et al. Outbreak of KPC-3-producing, and colistin-resistant, Klebsiella pneumoniae infections in two Sicilian hospitals. Clin Microbiol Infect 17 (2011), 1444–1447.
21. Sader, HS, Castanheira, M, Mendes, RE, Flamm, RK, Farrell, DJ, Jones, RN, Ceftazidime–avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013. Antimicrob Agents Chemother 59 (2015), 3656–3659.
22. Peleg, AY, Seifert, H, Paterson, DL, Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 21 (2008), 538–582.
23. Zavascki, AP, Carvalhaes, CG, Picao, RC, Gales, AC, Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther 8 (2010), 71–93.
24. Lister, PD, Wolter, DJ, Hanson, ND, Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 22 (2009), 582–610.
25. Weiner, LM, Webb, AK, Limbago, B, Dudeck, MA, Patel, J, Kallen, AJ, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014. Infect Control Hosp Epidemiol 37 (2016), 1288–1301.
26. Karlowsky, JA, Hoban, DJ, Hackel, MA, Lob, SH, Sahm, DF, Resistance among Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Latin American countries: SMART 2013–2015. Braz J Infect Dis 21 (2017), 343–348.
27. Karlowsky, JA, Hoban, DJ, Hackel, MA, Lob, SH, Sahm, DF, Antimicrobial susceptibility of Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia-Pacific countries: SMART 2013–2015. J Med Microbiol 66 (2017), 61–69.
28. Giammanco, A, Calà, C, Fasciana, T, Dowzicky, MJ, Global assessment of the activity of tigecycline against multidrug-resistant Gram-negative pathogens between 2004 and 2014 as part of the Tigecycline Evaluation and Surveillance Trial. mSphere 2 (2017), e00310–e00316.
29. World Health Organization. Antimicrobial resistance: global report on surveillance. 2014, WHO, Geneva, Switzerland.
30. Picão, R, Sader, H, Jones, R, Andrade, S, Gales, A, Analysis of resistance and vancomycin ‘reverse creep’ in Latin American Staphylococcus aureus: ten-year report of the SENTRY Antimicrobial Surveillance Program (1997–2006). Clin Microbiol Infect, 14, 2008, S173 (abstract P688).
31. Dantes, R, Mu, Y, Belflower, R, Aragon, D, Dumyati, G, Harrison, LH, et al. National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011. JAMA Intern Med 173 (2013), 1970–1978.
32. Gu, B, Kelesidis, T, Tsiodras, S, Hindler, J, Humphries, RM, The emerging problem of linezolid-resistant Staphylococcus. J Antimicrob Chemother 68 (2013), 4–11.
33. Flamm, RK, Mendes, RE, Hogan, PA, Streit, JM, Ross, JE, Jones, RN, Linezolid surveillance results for the United States (LEADER Surveillance Program 2014). Antimicrob Agents Chemother 60 (2016), 2273–2280.
34. ® Annual Appraisal of Potency and Spectrum; ZAAPS) program in European countries. J Chemother 23 (2011), 71–76.
35. Flamm, RK, Mendes, RE, Ross, JE, Sader, HS, Jones, RN, An international activity and spectrum analysis of linezolid: ZAAPS Program results for 2011. Diagn Microbiol Infect Dis 76 (2013), 206–213.
36. Jones, RN, Guzman-Blanco, M, Gales, AC, Gallegos, B, Castro, AL, Martino, MD, et al. Susceptibility rates in Latin American nations: report from a regional resistance surveillance program (2011). Braz J Infect Dis 17 (2013), 672–681.